Help us: Donate
Follow us on:
×

Menu

Back

Category: Press Releases

BioAge logo
BioAge Labs is developing a class of compounds that have been shown to inhibit the NLRP3 protein, which has been linked to all-cause mortality, in mouse models and human cells. These compounds can be taken orally and cross the blood-brain barrier. The full press release is included here. RICHMOND, Calif.--(BUSINESS WIRE)-- BioAge Labs, Inc. (“BioAge”,...
EARD2022 Banner
This year sees us hosting the fifth Ending Age-Related Diseases conference, and once again we are bringing you four action-packed days of aging research, rejuvenation biotechnology, and biotech investment. A virtual event focused on healthy longevity Join us on August 11-14 for what is sure to be an unmissable event for people interested in longer...
Rejuveron
The Rejuveron Age Better, Live Longer Symposium is only a few days away now! On May 10th, 2022 at 5:00 - 8:00 PM Central European Time, this one-day virtual event will explore the world of aging research and longevity. The event will consist of a series of three discussion panels, and you can join the...
BioAge logo
BioAge, a biotechnology company that intends to target aging on the molecular level, has completed a Phase 1b clinical trial of BGE-105, a small molecule that influences muscular metabolism. Here is the company's full press release. RICHMOND, Calif.--(BUSINESS WIRE)-- BioAge Labs, Inc., a biotechnology company developing therapeutics that target the molecular causes of aging to...
Elastrin
The well-known biotechnology holding company Kizoo has engaged in another funding round, this time for Elastrin Therapeutics, a company that focuses on returning stiff tissues to their natural state. The full press release is included here. Greenville, SC, U.S, April 7, 2022 – Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform to...
Insilico Medicine
Insilico Medicine, which uses AI for drug discovery, has identified potential dual-purpose therapeutic targets that are implicated in aging and age-associated diseases using artificial intelligence and a Hallmarks of Aging framework. The full press release is included here. March 29, 2022, New York (11AM ET) --- Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven...